Abstract
The prognostic significance of eosinophilia after myeloablative allogeneic stem cell transplantation (ASCT) remains to be established. Patients, whom developed chronic graft-versus-host disease (cGVHD) after ASCT, were included (n = 142). Eosinophil count was analyzed at cGVHD onset. We observed no significant association between EO and the grade of cGVHD, thrombocytopenia, nor extensive skin involvement. Importantly, we observed no significant association between cGVHD with concomitant eosinophilia and long-term clinical outcomes, and subgroup analyses revealed a considerable confounding effect of ongoing steroid treatment. In conclusion, we advocate that prognostic conclusions regarding cGVHD with concomitant eosinophilia after ASCT should be interpreted with caution.
Original language | English |
---|---|
Journal | Leukemia Research |
Volume | 38 |
Issue number | 3 |
Pages (from-to) | 334-9 |
Number of pages | 6 |
ISSN | 0145-2126 |
DOIs | |
Publication status | Published - Mar 2014 |
Keywords
- Adolescent
- Adult
- Blood Platelets
- Eosinophilia
- Eosinophils
- Female
- Glucocorticoids
- Graft vs Host Disease
- Hematopoietic Stem Cell Transplantation
- Humans
- Leukemia
- Male
- Middle Aged
- Myeloablative Agonists
- Prognosis
- Risk Factors
- Skin
- Transplantation, Homologous